Início › Linfoma de Burkitt › Ohio › Cincinnati
Ensaios clínicos de Linfoma de Burkitt em Cincinnati, OH
12 estudos para Linfoma de Burkitt estão buscando participantes em locais em Cincinnati e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecrutandoFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RecrutandoFase 3
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · a 15 mi de distância
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecrutandoEstudo observacional
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
RecrutandoFase 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · a 15 mi de distância
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecrutandoFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecrutandoFase 3
- University of Cincinnati Medical Center, Cincinnati
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
RecrutandoFase 3
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecrutandoFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecrutandoFase 3
- Cincinnati Children's Hospital Medical Center, Cincinnati
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RecrutandoFase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
RecrutandoFase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RecrutandoFase 1
- University of Cincinnati, Cincinnati
Ensaios de Linfoma de Burkitt em outras cidades
- Houston, TX21 estudos
- Milwaukee, WI16 estudos
- Philadelphia, PA16 estudos
- New York City, NY14 estudos
- Chicago, IL14 estudos
- Atlanta, GA12 estudos
- Seattle, WA11 estudos
- Boston, MA10 estudos
- Durham, NC10 estudos
- Aurora, CO10 estudos
- Los Angeles, CA10 estudos
- Kansas City, MO10 estudos
Outros estudos em Cincinnati
- Câncer de Pulmão de Não Pequenas Células35 estudos
- Câncer (todos os tipos)27 estudos
- Câncer de Mama25 estudos
- Insuficiência Cardíaca24 estudos
- Câncer Colorretal21 estudos
- Leucemia Mieloide Aguda20 estudos
- Câncer Metastático20 estudos
- Câncer de Ovário19 estudos
- Câncer de Pulmão19 estudos
- Obesidade19 estudos
- Câncer de Próstata18 estudos
- Mieloma Múltiplo17 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.